Amount Raised
$72 Million
Round Type
Series A
CambridgeBiotechnologyHealth CareScience And EngineeringDescription
Garuda Therapeutics, a company creating off-the-shelf, durable blood stem cell therapies, launched today with an oversubscribed $72 million Series A financing led by Aisling Capital, Northpond Ventures and Orbimed, supported by Cormorant Asset Management, Ridgeback Capital Investments, Monashee Investment Management, Sectoral Asset Management, National Resilience, Inc. (Resilience), Mass General Brigham Ventures, among others. Garuda is developing the world’s first, off-the-shelf hematopoietic stem cell platform that will eliminate dependency on donor or patient cells.
Quick answer
Garuda Therapeutics raised $72 Million in a Series A round, dated September 23, 2021. Garuda Therapeutics is based in Cambridge, Massachusetts, United States.
- How much did Garuda Therapeutics raise?
- Garuda Therapeutics raised $72 Million in a Series A round on September 23, 2021.
- What does Garuda Therapeutics do?
- Garuda Therapeutics seeks to eliminate the need for stem cell donors for blood stem cell transplants.
- Where is Garuda Therapeutics based and how big is it?
- Garuda Therapeutics is based in Cambridge, Massachusetts, United States. Fundz records about 55 employees.
- Who are the decision-makers at Garuda Therapeutics?
- Fundz holds 1 contact at Garuda Therapeutics. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Science And Engineering and Biotechnology around the same time
Companies in the same sectors as Garuda Therapeutics that raised within 45 days of this round, from Fundz verified event records.
- Cardurion Pharmaceuticals raised an undisclosed amount on October 27, 2021.
- Trait Biosciences Inc. raised $619K (Seed) on October 22, 2021.
- American Bitcoin raised $18M on October 20, 2021.
- Envisagenics raised $19M on October 19, 2021.
- Abalos raised an undisclosed amount (Series A) on October 14, 2021.
- MAIA Biotechnology raised $6.2M (Funding Round) on October 14, 2021.
Who to call at Garuda Therapeutics, and when
A new round usually means Garuda Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Garuda Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Garuda Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Garuda Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Garuda Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansGaruda Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.